ANTIBODY DEVELOPMENT FACILITY

抗体开发机构提供Fred哈钦森/华盛顿大学癌症联盟 （联合体）研究者使用定制设计的单克隆和重组（scFv）抗体。完整 单克隆抗体通过传统的杂交瘤技术产生，而重组抗体 通过噬菌体展示技术产生。含有Vh和VI链的重组抗体片段 通过阳性和阴性淘选在相关抗原上进行生物淘选来衍生scFv 技术.这两种技术的使用已经允许鉴定用于传统免疫的抗体。 蛋白质抗原的生物化学、细胞生物学和免疫学表征，DNA的产生 疫苗，以及用于鉴定针对非免疫原性抗体的高通量技术。 肽抗原以及生物标志物发现（scFv抗体阵列）。本申请 要求继续支持一个资源，继续履行一个重要的作用，为研究内， 财团

The Antibody Development Facility provides Fred Hutchinson/University of Washington Cancer Consortium (Consortium) investigators with custom designed monoclonal and recombinant (scFv) antibodies. Intact monoclonal antibodies are produced via traditional hybridoma technology while recombinant antibodies are produced via phage display technology. Recombinant antibody fragments containing Vh and VI chains (scFvs) are derived by bio panning on the relevant antigen via both positive and negative panning techniques. Use of both of these technologies has permitted the identification antibodies useful for traditional biochemical, cell biological and immunological characterization of protein antigens, the creation of DNA vaccines, as well as high through put technologies useful for identification of antibodies directed to nonimmunogenic peptide antigens as well as biomarker discovery (scFv antibody arrays). This application requests continued support for a resource which continues to fulfill an essential role for research within the Consortium.